Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study

Category	Detail
Condition	Coronary artery ectasia (CAE)
Key Mechanisms	Abnormal coronary dilation and slow flow leading to thrombotic complications.
Target Population	Patients with coronary artery ectasia receiving antithrombotic therapy.
Care Setting	Single-center retrospective cohort study.

Combination therapy with low-dose rivaroxaban and antiplatelet therapy reduced 36-month MACE risk (8.1% vs. 21.8%).
Significant absolute risk reduction of 13.7% with a number needed to treat of 7.3.
Greater benefits observed in patients with diffuse ectasia and elevated baseline D-dimer.
No significant difference in total bleeding rates between treatment groups.
A predictive model based on D-dimer and Markis classification was developed but not externally validated.

Coronary artery ectasia should be diagnosed through coronary angiography or computed tomography angiography.

Consider low-dose rivaroxaban in combination with single antiplatelet therapy for patients with CAE.

Assess the risk of major adverse cardiovascular events and bleeding in patients receiving antithrombotic therapy.

Patients with coronary artery ectasia.

Combination therapy may provide better long-term outcomes without increased bleeding risk.

Utilize a risk prediction model for individualized antithrombotic decision-making.
Follow up on biomarker changes to assess treatment efficacy.

Clinical Scorecard: Outcomes at 36 Months for Patients with Coronary Artery Ectasia Treated with Rivaroxaban and Antiplatelet Therapy: Insights from a Retrospective Cohort Analysis